NCT05249920View on ClinicalTrials.gov

Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,362

Participants

Timeline

Start Date

March 18, 2022

Primary Completion Date

February 17, 2023

Study Completion Date

May 19, 2023

Conditions
Acute Ischemic StrokeMechanical ThrombectomyEdaravone DexborneolPhase III
Interventions
DRUG

Edaravone Dexborneol Concentrated Solution for injection

Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.

DRUG

Edaravone Dexborneol placebo

Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.

Trial Locations (1)

100070

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER